Vaxart Management
Management criteria checks 3/4
Vaxart's CEO is Steven Lo, appointed in Mar 2024, has a tenure of 2.25 years. total yearly compensation is $2.81M, comprised of 23.1% salary and 76.9% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $284.11K. The average tenure of the management team and the board of directors is 4.3 years and 4.8 years respectively.
Key information
Steven Lo
Chief executive officer
US$2.8m
Total compensation
| CEO salary percentage | 23.13% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.3yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
BARDA Reliance And Funding Risks Will Shape Oral Vaccine Prospects Longer Term
Catalysts About Vaxart Vaxart is a clinical stage biotechnology company developing oral pill vaccines for infectious diseases such as COVID 19 and norovirus. What are the underlying business or industry changes driving this perspective?Vaxart, Inc. (NASDAQ:VXRT) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Vaxart, Inc. ( NASDAQ:VXRT ) shareholders would be excited to see that the share price has had a great month, posting a...Lacklustre Performance Is Driving Vaxart, Inc.'s (NASDAQ:VXRT) 36% Price Drop
Vaxart, Inc. ( NASDAQ:VXRT ) shareholders won't be pleased to see that the share price has had a very rough month...Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%
Vaxart, Inc. ( NASDAQ:VXRT ) shareholders would be excited to see that the share price has had a great month, posting a...Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding
The Vaxart, Inc. ( NASDAQ:VXRT ) share price has fared very poorly over the last month, falling by a substantial 29...There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump
Vaxart, Inc. ( NASDAQ:VXRT ) shares have had a really impressive month, gaining 39% after a shaky period beforehand...An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued
Key Insights The projected fair value for Vaxart is US$0.77 based on 2 Stage Free Cash Flow to Equity Current share...Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$37m |
| Dec 31 2025 | US$3m | US$650k | US$16m |
| Sep 30 2025 | n/a | n/a | -US$51m |
| Jun 30 2025 | n/a | n/a | -US$57m |
| Mar 31 2025 | n/a | n/a | -US$58m |
| Dec 31 2024 | US$2m | US$474k | -US$67m |
Compensation vs Market: Steven's total compensation ($USD2.81M) is above average for companies of similar size in the US market ($USD648.55K).
Compensation vs Earnings: Steven's compensation has been consistent with company performance over the past year.
CEO
Steven Lo (59 yo)
Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. From October 2019 to August 2022, Mr. Lo was the President, Chief Executive Officer and member of the board of direct...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.3yrs | US$2.81m | 0.23% $ 284.1k | |
| Senior VP & Chief Scientific Officer | 16.3yrs | US$1.14m | 0.15% $ 188.3k | |
| Chief Medical Officer | 4.8yrs | US$1.25m | 0.15% $ 185.9k | |
| CFO, Principal Accounting Officer & Principal Financial Officer | 1.1yrs | no data | 0.23% $ 276.6k | |
| Senior VP & General Counsel | 4.3yrs | no data | 0.11% $ 136.1k | |
| Senior Vice President of Human Resources | 1.4yrs | no data | no data | |
| Senior Vice President of Quality | 5.4yrs | no data | no data |
Experienced Management: VXRT's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.3yrs | US$2.81m | 0.23% $ 284.1k | |
| Member of Scientific & Clinical Advisory Board | 4.8yrs | no data | no data | |
| Independent Director | 3.8yrs | US$141.52k | 0.033% $ 40.8k | |
| Member of Scientific & Clinical Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 4.8yrs | no data | no data | |
| Independent Director | 5.2yrs | US$152.97k | 0.013% $ 15.6k | |
| Member of Scientific & Clinical Advisory Board | 4.8yrs | no data | no data | |
| Lead Independent Director | 3.8yrs | US$143.95k | 0.049% $ 59.9k | |
| Member of Scientific & Clinical Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 4.8yrs | no data | no data |
Experienced Board: VXRT's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/26 21:35 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaxart, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Roger Song | Jefferies LLC |
| null null | Oppenheimer & Co. Inc. |